上海医药：公司持续优化研发体系，搭建创新生态

Group 1 - The company is continuously optimizing its R&D system and building an innovative ecosystem to enhance R&D efficiency and increase investment in innovative research [1] - The self-developed drug SPH3127 for hypertension has been officially approved for market launch by December 2025 [1] - Several key pipelines are progressing in clinical trials, including B001 for neuromyelitis optica, which has completed the enrollment of all key study participants, and SRD4610 for amyotrophic lateral sclerosis, which has initiated Phase III clinical trials [1]